Gabriella M Anic1, Stephanie J Weinstein2, Alison M Mondul2, Satu Männistö3, Demetrius Albanes2. 1. Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, United States; Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. Electronic address: gabriella.anic@nih.gov. 2. Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. 3. Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland.
Abstract
OBJECTIVES: Vitamin D may prolong cancer survival by inhibiting tumor progression and metastasis, however, there are limited epidemiologic studies regarding the association between circulating 25-hydroxyvitamin D (25(OH)D) and lung cancer survival. The aim of this study was to examine the relationship between serum 25(OH)D and lung cancer specific survival and to evaluate whether vitamin D binding protein (DBP) concentration modified this association. MATERIALS AND METHODS: 25(OH)D and DBP were measured in fasting serum samples from 500 male lung cancer cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for lung cancer related death according to quartiles of season-specific 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, a proxy for free circulating 25(OH)D. RESULTS: Comparing highest to lowest quartiles, serum 25(OH)D (HR=1.18; 95% CI: 0.89-1.56) and DBP (HR=0.95; 95% CI: 0.71-1.26) were not associated with lung cancer survival and DBP concentration did not modify the association with 25(OH)D (p for interaction=0.56). There was suggestion of an association between higher serum 25(OH)D and better survival from adenocarcinoma (HR=0.64; 95% CI: 0.17-2.45) and small cell carcinoma (HR=0.55; 95% CI: 0.21-1.45), but these estimates were based on a relatively small number of cases. CONCLUSION: Serum 25(OH)D was not associated with overall lung cancer survival regardless of DBP concentration, however, these findings should be examined in other studies that include women and subjects with higher 25(OH)D levels. Published by Elsevier Ireland Ltd.
OBJECTIVES:Vitamin D may prolong cancer survival by inhibiting tumor progression and metastasis, however, there are limited epidemiologic studies regarding the association between circulating 25-hydroxyvitamin D (25(OH)D) and lung cancer survival. The aim of this study was to examine the relationship between serum 25(OH)D and lung cancer specific survival and to evaluate whether vitamin D binding protein (DBP) concentration modified this association. MATERIALS AND METHODS:25(OH)D and DBP were measured in fasting serum samples from 500 male lung cancer cases in the Alpha-Tocopherol, Beta-CaroteneCancer Prevention Study. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for lung cancer related death according to quartiles of season-specific 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, a proxy for free circulating 25(OH)D. RESULTS: Comparing highest to lowest quartiles, serum 25(OH)D (HR=1.18; 95% CI: 0.89-1.56) and DBP (HR=0.95; 95% CI: 0.71-1.26) were not associated with lung cancer survival and DBP concentration did not modify the association with 25(OH)D (p for interaction=0.56). There was suggestion of an association between higher serum 25(OH)D and better survival from adenocarcinoma (HR=0.64; 95% CI: 0.17-2.45) and small cell carcinoma (HR=0.55; 95% CI: 0.21-1.45), but these estimates were based on a relatively small number of cases. CONCLUSION: Serum 25(OH)D was not associated with overall lung cancer survival regardless of DBP concentration, however, these findings should be examined in other studies that include women and subjects with higher 25(OH)D levels. Published by Elsevier Ireland Ltd.
Entities:
Keywords:
25-hydroxyvitamin D; Cohort; Lung cancer; Serum vitamin D; Survival; Vitamin D binding protein
Authors: P Pietinen; A M Hartman; E Haapa; L Räsänen; J Haapakoski; J Palmgren; D Albanes; J Virtamo; J K Huttunen Journal: Am J Epidemiol Date: 1988-09 Impact factor: 4.897
Authors: T R Fears; R G Ziegler; J L Donaldson; R T Falk; R N Hoover; F Z Stanczyk; J B Vaught; M H Gail Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-04 Impact factor: 4.254
Authors: Rebecca Suk Heist; Wei Zhou; Zhaoxi Wang; Geoffrey Liu; Donna Neuberg; Li Su; Kofi Asomaning; Bruce W Hollis; Thomas J Lynch; John C Wain; Edward Giovannucci; David C Christiani Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: Stephanie J Weinstein; Alison M Mondul; Kai Yu; Tracy M Layne; Christian C Abnet; Neal D Freedman; Racheal Z Stolzenberg-Solomon; Unhee Lim; Mitchell H Gail; Demetrius Albanes Journal: Eur J Epidemiol Date: 2018-08-02 Impact factor: 8.082
Authors: Elizabeth Loehrer; Rebecca A Betensky; Edward Giovannucci; Li Su; Andrea Shafer; Bruce W Hollis; David C Christiani Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-11 Impact factor: 4.254
Authors: Stephanie J Weinstein; Alison M Mondul; Tracy M Layne; Kai Yu; Jiaqi Huang; Rachael Z Stolzenberg-Solomon; Regina G Ziegler; Mark P Purdue; Wen-Yi Huang; Christian C Abnet; Neal D Freedman; Demetrius Albanes Journal: JNCI Cancer Spectr Date: 2022-03-02
Authors: Michelle R Denburg; Andrew N Hoofnagle; Samir Sayed; Jayanta Gupta; Ian H de Boer; Lawrence J Appel; Ramon Durazo-Arvizu; Krista Whitehead; Harold I Feldman; Mary B Leonard Journal: J Bone Miner Res Date: 2016-06 Impact factor: 6.741